about
Melanized fungi in human diseaseToxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B.Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a di-stigma-steryl-hemi-succinoyl-glycero-phosphocholine liposome-intercalated amphotericin B.The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Management of mycoses in neutropenic patients: a brief history, 1960-2008Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans.Novel approaches to antifungal prophylaxis.Preparation and antifungal activity of spray-dried amphotericin B-loaded nanospheres.Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model.Use of terbinafine in rare and refractory mycoses.Targeted delivery of nucleic-acid-based therapeutics to the pulmonary circulation.Optimizing efficacy of Amphotericin B through nanomodification.Recent advances in intravenous delivery of poorly water-soluble compounds.Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics.Biodistribution and In Vivo Antileishmanial Activity of 1,2-Distigmasterylhemisuccinoyl-sn-Glycero-3-Phosphocholine Liposome-Intercalated Amphotericin B.Biomimetically engineered Amphotericin B nano-aggregates circumvent toxicity constraints and treat systemic fungal infection in experimental animals.Reduction of amphotericin B-induced renal tubular apoptosis by N-acetylcysteine.Successful treatment of patients with respiratory failure due to fungal infection after allogeneic hematopoietic stem cell transplantation.Anti-biofilm activity of a sophorolipid-amphotericin B niosomal formulation against Candida albicans.A Computational Approach Using Bioinformatics to Screening Drug Targets for Leishmania infantum Species.
P2860
Q24633163-2AFA7481-1651-4C98-B46C-F7A3AB369164Q33409652-798320BE-E598-44E5-AE65-95D82EDBF334Q34763371-6E04783C-4E5F-471B-AA49-FD5A8480BA6FQ35127510-F5F74B8F-B22A-4A26-AF2F-70261EB08830Q35168703-F93B81B8-03C8-414E-8265-69D37B8F91F2Q35790799-E4A5C7C2-6CEB-42AC-8D67-E3A91BA0198EQ35832248-D049324F-6049-437C-8ED8-45E0D88DBB90Q35840760-4FE6825A-64FC-4F76-9BFB-04A8314D7729Q37071133-DD325790-5FBF-4EF6-AC19-83AC47236A3AQ37149082-C82EC1AF-C7C2-4F75-BB63-50F8A8FE6F66Q37178176-162B0BA5-ABA2-4965-A0A5-9B4EF3227EA5Q37639306-AFAD4866-F130-43D3-8F33-F261F52E529DQ37904672-3452CEB5-995E-429B-A2CD-06A44418FBBEQ40166247-13BEC3B2-555C-4D24-B72D-39AEC027035DQ41703512-0AF5E847-9902-4677-808F-CBA0735B6E9CQ43102684-2AD2FA53-D868-4120-BFF0-FD39FE188AF7Q47230940-F7FF4378-1387-4A91-9AEC-4B6B881F7F53Q47634017-EF535AD0-2CCC-4F00-964C-876E0950E1DEQ54943993-A170491A-99BD-4B89-9E95-8EB43E57A8CD
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The lipid formulations of amphotericin B.
@ast
The lipid formulations of amphotericin B.
@en
type
label
The lipid formulations of amphotericin B.
@ast
The lipid formulations of amphotericin B.
@en
prefLabel
The lipid formulations of amphotericin B.
@ast
The lipid formulations of amphotericin B.
@en
P2093
P2860
P1476
The lipid formulations of amphotericin B.
@en
P2093
Raoul Herbrecht
Shanti Natarajan-Amé
Valérie Letscher-Bru
Yasmine Nivoix
P2860
P304
P356
10.1517/14656566.4.8.1277
P407
P577
2003-08-01T00:00:00Z